Allergy Therapeutics (GB:AGY) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Allergy Therapeutics has submitted a Marketing Authorisation Application to Germany’s Paul Ehrlich Institut for its innovative Grass MATA MPL allergy treatment. This submission marks a crucial step in the regulatory process for the subcutaneous immunotherapy designed to alleviate symptoms of grass pollen allergies. The application is supported by comprehensive data, including a pivotal Phase III trial showcasing significant efficacy over placebo.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.